Optimizing Tissue Sampling for the Diagnosis, Subtyping, and Molecular Analysis of Lung Cancer

Ofiara, Linda; Navasakulpong, Asma; Beaudoin, Stéphane; Gonzalez, Anne V.

doi:10.3389/fonc.2014.00253

Cited by 37 publications

(24 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bronchoscopic cryobiopsy directly addresses these requirements, since the specimens are of large size, of good quality and with fewer artifacts [15,20,38,39] compared to other biopsy or aspiration techniques. The size, representative nature and quality of tissue preservation found in cryo-biopsy specimens compared to forceps biopsy specimens probably explains the improved EGFR detection rate.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, representative tumour tissue of adequate volume and quality forms the basis for optimal histological and molecular evaluation. EGFR testing lays the cornerstone for current NSCLC treatment in advanced stages [15]. Apart from surgical resection and radiologically guided biopsies, the standard techniques to obtain tissue samples in patients with suspected lung cancer are bronchoscopic forceps biopsy and fine needle aspiration [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

A B S T R A C TObjectives: Detection of activating epidermal growth factor receptor (EGFR) mutation is crucial for individualized treatment of advanced non-small-cell lung cancer (NSCLC). However little is known about how biopsy technique affects the detection rate of EGFR mutations. This retrospective, single center study evaluated the detection rate of EGFR mutations in tissue obtained by bronchoscopic cryobiopsy and compared this to other standard tissue sampling techniques. Materials and methods: We retrospectively analyzed 414 patients with histologically confirmed NSCLC and known EGFR mutation status between 3/2008-7/2014. Tumor specimens obtained by tissue preserving bronchoscopic cryobiopsy were compared to those obtained by other techniques. Results and conclusion: Analysis of bronchoscopic cryobiopsy tissue detected 29 activating EGFR mutations in 27 (21.6 %) out of 125 patients, while analysis of tissue obtained by non-cryobiopsy techniques (bronchoscopic forceps biopsies, fine needle aspiration, imaging guided transthoracical and surgical procedures) detected 42 EGFR mutations in 40 (13.8 %) out of 298 patients (p < 0.05). Cryobiopsy increased detection rate of EGFR mutations in central tumors compared with forceps biopsy (19.6 % versus 6.5 %, p < 0.05), while an insignificant trend was detected also for peripheral tumors (33.3 % versus 26.9 %).Bronchosopic cryobiopsy increases the detection rate of activating EGFR mutations in NSCLC in comparison to other tissue sampling techniques. This will help to optimize individualized treatment of patients with advanced tumors. Because of the retrospective nature of this analysis, a prospective trial is mandatory for final assessment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Material obtained by any of those methods is considered adequate for testing 8 . The diagnostic accuracy and adequacy of the biopsy samples depends on its diagnostic modality and the diameter of the needles used 9,10,11,12,13,14 . To date, there has been no consensus on the number of tumor cells (TC) necessary for EGFR molecular testing.…”

Section: Introductionmentioning

confidence: 99%

Adequacy of biopsy samples for epidermal growth factor receptor (EGFR) molecular testing in lung adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Background/Aim. Adenocarcinoma of the lung is the most common histological type of lung cancer. The most reliable method in detecting EGFR mutations is real-time PCR. It is recommended to sample three to five biopsy samples with a minimum of 200-400 preserved tumor cells. We analyzed the suitability of biopsy samples for EGFR molecular testing in lung adenocarcinoma.Methods. This retrospective analysis included 60 patients diagnosed with lung adenocarcinoma in the Institute for Pulmonary Diseases in Sremska Kamenica, during the period 2010-2015. Biopsy samples were obtained using transbronchial, bronchoscopic or catheter biopsy procedure. All cases included the identification of morphometric parameters, concentration of isolated DNA and EGFR mutations. The proportion of tumor in biopsy samples was assessed in histological sections using computer-aided morphometry. Results. Biopsy samples were most commonly obtained by transbronchial biopsy (63%). In 35% of cases there were one and two biopsy samples. More than 10% of tumor cells were found in 68% of cases, while the majority of cases (33%) had between 200 and 500 of tumor cells and only 8% of cases had between 20 and 50 tumor cells. The average concentration of DNA in all analyzed samples was 5.81 ng/µl and was significantly lower in samples provided by catheter biopsy. Only two cases with mutations were detected, and there was no statistically significant difference between the concentrations of isolated DNA in wilde type and mutated EGFR adenocarcinoma. Invalid results were found in 10% of cases. Conclusion. Biopsy samples are suitable for EGFR molecular testing in lung adenocarcinoma.

show abstract

“…2 The gold standard for diagnosing lung cancer is by histological analyses of biopsies, which is more accurate than other tests, for example cytology or analysis of sputum. 3 There are several different techniques that can be used to biopsy the lung but obtaining a biopsy adequate for histological diagnoses can be difficult as the biopsy must be physiologically intact. Some techniques can cause damage to the biopsies making them unsuitable for histological analyses.…”

Section: Introductionmentioning

confidence: 99%

Assessing dysplasia of a bronchial biopsy with FTIR spectroscopic imaging

et al. 2015

View full text Add to dashboard Cite

An FTIR image of an 8 µm section of de-paraffinised bronchial biopsy that shows a histological transition from normal to severe dysplasia/squamous cell carcinoma (SCC) in situ was obtained in transmission by stitching together images of 256 x 256 µm recorded using a 96 x 96 element FPA detector. Each pixel spectrum was calculated from 128 co-added interferograms at 4 cm −1 resolution. In order to improve the signal to noise ratio, blocks of 4x4 adjacent pixels were subsequently averaged. Analyses of this spectral image, after conversion of the spectra to their second derivatives, show that the epithelium and the lamina propria tissue types can be distinguished using the area of troughs at either 1591, 1334, 1275 or 1215 cm −1 or, more effectively, by separation into two groups by hierarchical clustering (HCA) of the 1614-1465 region. Due to an insufficient signal to noise ratio, disease stages within the image could not be distinguished with this extent of pixel averaging. However, after separation of the cell types, disease stages within either the epithelium or the lamina propria could be distinguished if spectra were averaged from larger, manually selected areas of the tissue. Both cell types reveal spectral differences that follow a transition from normal to cancerous histology. For example, spectral changes that occurred in the epithelium over the transition from normal to carcinoma in situ could be seen in the 1200-1000 cm −1 region, particularly as a decrease in the second derivative troughs at 1074 and 1036 cm −1 , consistent with changes in some form of carbohydrate. Spectral differences that indicate a disease transition from normal to carcinoma in the lamina propria could be seen in the 1350-1175 cm −1 and 1125-1030 cm −1 regions. Thus demonstrating that a progression from healthy to severe dysplasia/squamous cell carcinoma (SCC) in situ can be seen using FTIR spectroscopic imaging and multivariate analysis.

show abstract

Optimizing Tissue Sampling for the Diagnosis, Subtyping, and Molecular Analysis of Lung Cancer

Cited by 37 publications

References 58 publications

Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer

Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer

Adequacy of biopsy samples for epidermal growth factor receptor (EGFR) molecular testing in lung adenocarcinoma

Assessing dysplasia of a bronchial biopsy with FTIR spectroscopic imaging

Contact Info

Product

Resources

About